BioCentury
ARTICLE | Clinical News

Revefenacin: Phase III started

September 21, 2015 7:00 AM UTC

Theravance began a pair of double-blind, placebo-controlled Phase III trials to evaluate 88 and 175 ug inhaled revefenacin via nebulizer once daily for 12 weeks in about 618 patients each. Data from t...